{"entity":{"id":"benjamin-besse","kind":"person","name":"Benjamin Besse","aka":[],"tldr":"Benjamin Besse is a lung cancer trialist central to the Dato-DXd and HER3-DXd lung programmes.","summary":"Benjamin Besse is Head of Clinical Research at Gustave Roussy and a thoracic oncologist. His specialisms are thoracic oncology, antibody-drug conjugates in lung cancer and oncogene-driven non-small-cell lung cancer. He is a principal investigator in the TROPION-Lung and HERTHENA-Lung programmes, which test datopotamab deruxtecan and patritumab deruxtecan in lung cancer, and in trials of targeted therapy for oncogene-driven disease. His Journal of Clinical Oncology paper on TROPION-Lung01 compared datopotamab deruxtecan with docetaxel in previously treated advanced or metastatic non-small-cell lung cancer. He is linked to the TROPION-Lung01 and HERTHENA-Lung02 trials, and his publications are listed on PubMed.","asOf":"2026-09-08","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Besse%20B%5BAuthor%5D%20lung%20deruxtecan"}],"tags":[],"related":[],"cancers":["nsclc"],"sections":[],"technologies":[],"targets":[],"drugs":["datopotamab-deruxtecan","patritumab-deruxtecan"],"companies":[],"institutions":["gustave-roussy"],"pathways":[],"terms":[],"trials":["tropion-lung01","herthena-lung02"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Head of Clinical Research, Gustave Roussy; thoracic oncologist","institutionId":"gustave-roussy","specialisms":["Thoracic oncology","ADCs in lung cancer","Oncogene-driven NSCLC"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Besse%20B%5BAuthor%5D%20lung%20deruxtecan"}],"papers":[{"title":"Datopotamab deruxtecan versus docetaxel for previously treated advanced or metastatic non-small cell lung cancer (TROPION-Lung01)","journal":"JCO","year":2025,"doi":"10.1200/JCO-24-01544"},{"title":"MARIPOSA: amivantamab plus lazertinib versus osimertinib as first treatment for EGFR-mutated lung cancer","journal":"New England Journal of Medicine","year":2024,"url":"https://doi.org/10.1056/NEJMoa2403614","doi":"10.1056/NEJMoa2403614"}],"orcid":"0000-0001-5090-8189"},"route":"/people/benjamin-besse/","neighbours":{"cancer":[{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"}],"drug":[{"id":"datopotamab-deruxtecan","kind":"drug","name":"Datopotamab deruxtecan","route":"/drugs/datopotamab-deruxtecan/"},{"id":"patritumab-deruxtecan","kind":"drug","name":"Patritumab deruxtecan","route":"/drugs/patritumab-deruxtecan/"}],"institution":[{"id":"gustave-roussy","kind":"institution","name":"Gustave Roussy","route":"/institutions/gustave-roussy/"}],"trial":[{"id":"herthena-lung02","kind":"trial","name":"HERTHENA-Lung02","route":"/trials/herthena-lung02/"},{"id":"tropion-lung01","kind":"trial","name":"TROPION-Lung01","route":"/trials/tropion-lung01/"}],"paper":[{"id":"paper-mariposa-nejm-2024","kind":"paper","name":"MARIPOSA: amivantamab plus lazertinib versus osimertinib as first treatment for EGFR-mutated lung cancer","route":"/key-papers/paper-mariposa-nejm-2024/"}],"company":[{"id":"ifct","kind":"company","name":"Intergroupe Francophone de Cancérologie Thoracique","route":"/companies/ifct/"}]}}